Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4)Trial

Now Enrolling!

If you do not have memory changes that exceed normal age-related changes and are interested in participating in a clinical drug trial designed to prevent Alzheimer's dementia, please click on this link to see if the A4 trial is a fit for you. If so, contact Chritsina Gigliotti, PhD for more information.

ADRC Co-Authors New DLB Booklet with NIA and LBDA

The Shiley-Marcos ADRC has co-authored a new Lewy Body Dementia booklet with NIA and LBDA. Click the link below to access the online publication and order print copies. http://www.nia.nih.gov/sites/default/files/lewy_body_dementia_0.pdf

Are you 60 or older and noticing changes in your sense of smell?

The Parkinson's Progression Markers Initiative (PPMI) is a landmark observational study designed to help define biomarkers, or indicators of Parkinson's disease (PD) progression. PPMI has added a new arm to the existing study that will investigate certain risk factors of PD. By better understanding risk factors, such as smell loss, doctors may be able to identify people with Parkinson’s before the onset of motor symptoms. Early detection is a crucial step in understanding the causes of PD and developing better treatments for Parkinson’s disease.

The task of identifying risk factors for PD offers friends and family of people with Parkinson’s a unique role to play in Parkinson’s research. People who are over the age of 60 and who do not have Parkinson’s are needed for this study that will assess the relationship between Parkinson’s and sense of smell. Find out if you are eligible to participate by taking the smell survey at www.michaeljfox.org/takethesmellsurvey or call (877) 525-PPMI. If you have Parkinson’s disease, we need your help to reach the 10,000 people without PD who may qualify. Invite family and friends to follow their noses to research that could make a difference for Parkinson’s research.  UC San Diego is a site for this research study, and you may also contact  Christina Gigliotti, Ph.D. at 858-246-1243 for additional information.

Have Concerns About Memory or Thinking but Unable to Attend Our

Memory Screening Event?

You can call the MAP program or the Parkinson's Disease Research Consortium at the Shiley-Marcos Alzheimer's Disease Research Center to schedule a no-cost screening appointment at your convenience. Participants with Parkinson's disease must be 60 or older. Call (858) 822-4800 to schedule your screening or for more information.

Click here to view the video featuring Irene Litvan MD, UC San Diego Health systems discussing changes in thinking in Parkinson's disease

NIH Releases New Alzheimer's Disease Progress Report - 2012-2013

Click here to access the online issue of this progres report and watch the numerous video interviews with the nation's leading scientists.

Fox Trial Finder Officially Launches

The Michael J. Fox Foundation for Parkinson's Research announced the official launch of Fox Trial Finder whose goal is to get 10,000 volunteers willing to participate in their research now and into the future. Click here to get more information or register in the Fox Trial Finder.

The ADEAR Center is now on Twitter!

Follow @Alzheimers NIH for daily tweets linking you to:

• News about Alzheimer's and related research
• Alzheimer's facts and tips
• caregiving resources
• information about Alzheimer's clinical trials

@Alzheimer's NIH is a great resource for researchers, professionals, and caregivers. Follow us today and start sharing ADEAR Center information with your own followers.

Alzheimers.gov launched

In conjunction with the release of the National Alzheimer’s Plan, the U.S. Department of Health and Human Resources (HHS) launched a critical new resource for families and individuals facing Alzheimer’s. A new website, alzheimers.gov, and an accompanying ad campaign were developed by HHS in collaboration with the Alzheimer’s Association to help raise awareness and provide support to those living with the disease. The ad campaign will begin later this summer.